The news is by your side.


Sanofi digs deep to buy US haemophilia group Bioverativ for $11.6 billion

PARIS: French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. Sanofi shares fell 3.4 percent by 0920 GMT, making the stock the worst performer on France’s benchmark CAC-40 index and several analysts deemed the deal expensive. The move comes at a time of renewed interest by large drugmakers in smaller biotech firms and predictions by some experts that 2018 will…

Dengue vaccine not deadly, says maker

MANILA: A world-first dengue vaccination programme in the Philippines that was suspended over safety concerns will not cause anyone who was immunised to die, drug manufacturer Sanofi and local authorities said on Monday. The Philippines on Friday suspended the programme, after more than 733,000 people had been immunised, in response to a statement from Sanofi that its vaccine could cause "more cases of severe disease" for people who had not previously had the mosquito-borne ailment. After news outlets and some…